Compare NGVT & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVT | SNDX |
|---|---|---|
| Founded | 1964 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | N/A | 2016 |
| Metric | NGVT | SNDX |
|---|---|---|
| Price | $72.27 | $20.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $67.50 | ★ $80.23 |
| AVG Volume (30 Days) | 287.7K | ★ 1.2M |
| Earning Date | 02-18-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,382,100,000.00 | $111,304,000.00 |
| Revenue This Year | N/A | $617.40 |
| Revenue Next Year | $2.35 | $115.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 5.63 | ★ 595.65 |
| 52 Week Low | $28.49 | $8.58 |
| 52 Week High | $73.20 | $22.73 |
| Indicator | NGVT | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 74.10 | 49.06 |
| Support Level | $63.56 | $19.99 |
| Resistance Level | $69.80 | $21.89 |
| Average True Range (ATR) | 2.34 | 1.05 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 90.46 | 35.21 |
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.